

04 March 2025

---

### **Momentous court victory for SA pharmaceutical company against multinational giant**

A favourable legal outcome in the challenge of the South African patent for enzalutamide has allowed Eurolab to continue supplying enzalutamide at a significantly reduced price.

Following a court ruling challenging the South African patent for enzalutamide (held by the Regents of the University of California and licensed to Astellas Pharma), the original South African patent was declared invalid. This ruling paved the way for Eurolab to continue supplying enzalutamide to the local market as it has been doing since its launch in April 2024. Given the financial strain often associated with cancer treatment, we remain committed to providing high-quality, affordable oncology solutions to support better patient outcomes. This case represents a major victory for South African cancer patients.

---

#### **About Eurolab (Pty) Ltd:**

In 2011, the establishment of Eurolab marked a significant step towards diminishing the financial burdens associated with cancer care in South Africa. Our primary mission revolves around enhancing the accessibility and affordability of cancer care, catering to the needs of patients battling this disease. Through its progression, Eurolab has been able to expand and introduce innovation into South Africa's cancer care environment offering diverse options for cancer treatment and recovery. Eurolab's journey is far from over. We persistently delve into novel strategies aimed at introducing innovative products and initiatives into the South African landscape. Our unwavering commitment to maintaining a balance between cost-effectiveness and quality is what distinguishes us, ultimately making cancer treatment a more attainable reality for a wider segment of the South African population.